Department of Hepatobiliary Surgery, Hainan Provincial People's Hospital, Haikou, China.
Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):388-396. doi: 10.26355/eurrev_201801_14185.
This study aimed at exploring the expression and prognostic values of a novel long noncoding RNA RUSC1-AS-N in hepatocellular carcinoma (HCC), and to investigate the biological roles of RUSC1-AS-N in HCC cells.
RUSC1-AS-N expression in public available microarray data was analyzed. The expression of RUSC1-AS-N in our cohort containing 66 HCC tissues and paired adjacent non-cancerous hepatic tissues was measured by qRT-PCR. The correlation between RUSC1-AS-N expression and clinicopathological characteristics was evaluated by Pearson χ2-test. The prognostic value of RUSC1-AS-N was analyzed by Kaplan-Meier survival analysis. The biological roles of RUSC1-AS-N on HCC cell viability were evaluated by Glo cell viability assays and Ethynyl deoxyuridine incorporation assays. The effects of RUSC1-AS-N on HCC cell cycle were evaluated by fluorescence-activated cell sorting (FACS) analyses of propidium-iodide (PI) stained cells. The effects of RUSC1-AS-N on HCC cell apoptosis were evaluated by TdT-mediated dUTP nick end-labeling (TUNEL) assays.
RUSC1-AS-N is upregulated in HCC tissues and associated with poor prognosis of HCC patients from GSE54238 and GSE40144. In our cohort, we further confirmed the upregulation of RUSC1-AS-N in HCC tissues. High expression of RUSC1-AS-N associates with large tumor size, vein invasion, encapsulation incompletion, advanced BCLC stage, and poor recurrence-free survival and overall survival. Functional assays revealed that RUSC1-AS-N knockdown markedly decreases cell viability, induces cell-cycle arrest and apoptosis of HCC cells.
RUSC1-AS-N is upregulated and acts as an oncogene in HCC. RUSC1-AS-N may be a promising prognostic biomarker and therapeutic target for HCC.
本研究旨在探讨新型长链非编码 RNA RUSC1-AS-N 在肝细胞癌（HCC）中的表达及预后价值，并研究其在 HCC 细胞中的生物学作用。
分析公共可用的微阵列数据中 RUSC1-AS-N 的表达情况。采用 qRT-PCR 检测我们的 66 例 HCC 组织和配对的癌旁非肿瘤组织中的 RUSC1-AS-N 表达。采用 Pearson χ2 检验评估 RUSC1-AS-N 表达与临床病理特征的相关性。采用 Kaplan-Meier 生存分析评估 RUSC1-AS-N 的预后价值。通过 Glo 细胞活力测定和 Ethynyl deoxyuridine 掺入测定评估 RUSC1-AS-N 对 HCC 细胞活力的生物学作用。通过碘化丙啶（PI）染色细胞的荧光激活细胞分选（FACS）分析评估 RUSC1-AS-N 对 HCC 细胞周期的影响。通过 TdT 介导的 dUTP 缺口末端标记（TUNEL）测定评估 RUSC1-AS-N 对 HCC 细胞凋亡的影响。
RUSC1-AS-N 在 HCC 组织中上调，与 GSE54238 和 GSE40144 中 HCC 患者的不良预后相关。在我们的队列中，我们进一步证实了 RUSC1-AS-N 在 HCC 组织中的上调。RUSC1-AS-N 的高表达与肿瘤体积大、静脉侵犯、包膜不完整、BCLC 分期较晚以及无复发生存和总生存不良相关。功能测定表明，RUSC1-AS-N 敲低显著降低 HCC 细胞的活力，诱导细胞周期停滞和细胞凋亡。
RUSC1-AS-N 在 HCC 中上调并发挥癌基因作用。RUSC1-AS-N 可能是 HCC 有前途的预后标志物和治疗靶点。
